MX2022010407A - Forma de dosis oral de rápida dispersión de rimegepant. - Google Patents

Forma de dosis oral de rápida dispersión de rimegepant.

Info

Publication number
MX2022010407A
MX2022010407A MX2022010407A MX2022010407A MX2022010407A MX 2022010407 A MX2022010407 A MX 2022010407A MX 2022010407 A MX2022010407 A MX 2022010407A MX 2022010407 A MX2022010407 A MX 2022010407A MX 2022010407 A MX2022010407 A MX 2022010407A
Authority
MX
Mexico
Prior art keywords
rimegepant
dosage form
dispersing dosage
fast
oral fast
Prior art date
Application number
MX2022010407A
Other languages
English (en)
Inventor
Vladimir Coric
Robert Croop
Charles M Conway
Marianne Frost
Original Assignee
Biohaven Pharm Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharm Holding Co Ltd filed Critical Biohaven Pharm Holding Co Ltd
Publication of MX2022010407A publication Critical patent/MX2022010407A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona una forma de dosis de rápida dispersión para administración oral, en donde la forma de dosis de rápida dispersión incluye un rimegepant. También se proporciona un 5 método para administrar rimegepant a un sujeto, en donde el método incluye administrar por vía oral al sujeto una composición que incluye una forma de dosis de rápida dispersión que incluye rimegepant.
MX2022010407A 2020-02-27 2021-02-26 Forma de dosis oral de rápida dispersión de rimegepant. MX2022010407A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062982456P 2020-02-27 2020-02-27
PCT/US2021/019825 WO2021173936A1 (en) 2020-02-27 2021-02-26 Oral fast-dispersing dosage form of rimegepant

Publications (1)

Publication Number Publication Date
MX2022010407A true MX2022010407A (es) 2022-11-07

Family

ID=77492027

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010407A MX2022010407A (es) 2020-02-27 2021-02-26 Forma de dosis oral de rápida dispersión de rimegepant.

Country Status (11)

Country Link
US (1) US20230108049A1 (es)
EP (1) EP4110337A4 (es)
JP (1) JP2023515535A (es)
KR (1) KR20220146535A (es)
CN (1) CN115335051A (es)
AU (1) AU2021227937A1 (es)
BR (1) BR112022016790A2 (es)
CA (1) CA3172358A1 (es)
IL (1) IL295926A (es)
MX (1) MX2022010407A (es)
WO (1) WO2021173936A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230015324A (ko) * 2020-03-29 2023-01-31 바이오헤이븐 파마슈티컬 아일랜드 디에이씨 편두통의 예방적 치료
WO2023175632A1 (en) * 2022-03-17 2023-09-21 Msn Laboratories Private Limited, R&D Center Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9026998D0 (en) * 1990-12-12 1991-01-30 Glaxo Group Ltd Medicaments
CN110636834A (zh) * 2017-02-15 2019-12-31 分子浸剂有限公司 制剂
BR112020019396A2 (pt) * 2018-03-25 2021-01-05 Biohaven Pharmaceutical Holding Company Ltd. Rimegepant para distúrbios relacionados a cgrt

Also Published As

Publication number Publication date
CN115335051A (zh) 2022-11-11
JP2023515535A (ja) 2023-04-13
BR112022016790A2 (pt) 2022-11-08
EP4110337A4 (en) 2024-03-20
EP4110337A1 (en) 2023-01-04
WO2021173936A1 (en) 2021-09-02
AU2021227937A1 (en) 2022-09-08
KR20220146535A (ko) 2022-11-01
CA3172358A1 (en) 2021-09-02
US20230108049A1 (en) 2023-04-06
IL295926A (en) 2022-10-01

Similar Documents

Publication Publication Date Title
MX2022010407A (es) Forma de dosis oral de rápida dispersión de rimegepant.
ZA201608614B (en) Solid oral pharmaceutical compositions for isoxazoline compounds
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
SI1746980T1 (sl) Farmacevtska dozirna oblika ki obsega pelete kot tudi postopek za njeno pripravo
NZ597488A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
MX2021014774A (es) Formulaciones de liberacion modificada y usos de las mismas.
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
PH12021550218A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
MX2021015827A (es) Antagonista de neurokinin -1.
MX2021014523A (es) Metodos para tratar colangiocarcinoma.
MX2013003523A (es) Composicion farmaceutica de dosis baja.
BR112018068784A2 (pt) método para o tratamento de leucemia
MX2023003758A (es) Formulaciones farmaceuticas.
MX2022011651A (es) Composicion farmaceutica para tratamiento de diabetes.
MX2022016341A (es) Formas farmaceuticas de maleato de acalabrutinib.
MX2022013884A (es) Compuestos de metiltioninio para usarse en el tratamiento de hipoxemia.
TW201613606A (en) Therapeutic drug for chronic renal failure
MX2022000426A (es) Telmisartan para el tratamiento de la hipertension en perros.
MX2023013983A (es) Metodo de tratamiento del temblor esencial.
MX2024000084A (es) Compuesto de tiazololactama dimetil sustituido y uso de este.
JP1770167S (ja) 投薬用鼻腔挿入器
UA95834U (uk) Спосіб лікування гострого ішемічного інсульту
UA115803U (xx) Спосіб лікування вертеброгенних радикулопатій
UA74059U (ru) Способ комплексного лечения эхинококковой болезни